Correlation between EGFR gene mutations and clinical characteristics among lung cancer patients in Shanghai

doi:10.3969/j.issn.1673-8640.2017.01.008

Abstract

Abstract:

Objective To study the mutations of epidermal growth factor receptor （EGFR）gene and the correlation with the clinical characteristics of lung cancer patients in Shanghai. Methods A total of 207 paraffin-embedded tissue samples from lung cancer patients were collected. The mutations of EGFR gene were determined by real-time fluorescence quantitation polymerase chain reaction（PCR） after DNA extraction. Results The EGFR gene mutation rate was 47.34%,and there were correlations with sex and pathological types （P<0.01）,while there was no correlation with age （P>0.05）. The mutation types of EGFR gene were not correlated with sex and age （P>0.05）. EGFR gene mutation status of lung adenocarcinoma patients was not correlated with its pathological classification（P>0.05）. Conclusions EGFR gene mutations in Shanghai are correlated with the clinical characteristics of lung cancer patients. EGFR gene mutation occurs more frequently in females and in patients with lung adenocarcinoma.

Key words: Epidermal growth factor receptor, Lung cancer, Mutation, Sex, Age, Pathological classification

CLC Number:

R446.1

JIANG Wenrong, CAI Yongjun, MIAO Yingxin, JIN Jingjing, XIAO Li, YANG Feng, YIN Yulei, ZHANG Yanmei, ZHAO Hu. Correlation between EGFR gene mutations and clinical characteristics among lung cancer patients in Shanghai[J]. Laboratory Medicine, 2017, 32(1): 30-34.

Figures/Tables 3

References 30

1	JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
2	SIBILIA M,KROISMAYR R,LICHTENBERGER B M,et al.The epidermal growth factor receptor: from development to tumorigenesis[J]. Differentiation,2007,75(9):770-787.
3	萨姆布鲁克 J,弗 F,曼尼阿蒂斯 T. 分子克隆实验指南[M]. 2版. 北京:科学出版社,1999:304-325.
4	HIGUCHI R,FOCKLER C,DOLLINGER G,et al.Kinetic PCR analysis: real-time monitoring of DNA amplification reactions[J]. Biotechnology (N Y),1993,11(9):1026-1030.
5	National Comprehensive Cancer Network. Non-small cell lung cancer clinical practice guidelines in oncology[S]. NCCN,2015.
6	谢飞,程德云,樊莉莉,等. 西南地区原发性肺腺癌患者EGFR基因突变率分析[J]. 四川医学,2014,35(5):624-625.
7	王京伟,李艳,童永清,等. 湖北地区非小细胞肺癌EGFR基因突变及其意义的研究[J]. 现代检验医学杂志,2016,31(3):7-11.
8	RIELY G J,PAO W,PHAM D,et al.Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib[J]. Clin Cancer Res,2006,12(3 Pt 1):839-844.
9	董丹丹,唐源,邹艳,等. 四川地区肺腺癌中EGFR基因19、21外显子突变研究[J]. 临床与实验病理学杂志,2011,27(12):1306-1309.
10	人类年龄段划分新标准[J]. 现代养生,2005,21(9):16.
11	张蓉,陈薇雅,甘洁民,等. EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析[J]. 检验医学,2013,28(6):506-510.
12	刘伟. 肺腺癌2011年国际新分类[J]. 实用癌症杂志,2012,27(4):432-434.
13	景晓刚. 肺癌外周血EGFR基因突变高灵敏检测方法的建立[D]. 郑州:郑州大学,2015.
14	刘红雨. 187例非小细胞肺癌中EGFR基因突变和扩增的检测及其临床意义[J]. 中国肺癌杂志,2009,12(12):1219-1228.
15	CLEGG R M.Fluorescence resonance energy transfer[J]. Curr Opin Biotechnol,1995,6(1):103-110.
16	ZHOU L,MYERS A N,VANDERSTEEN J G,et al.Closed-tube genotyping with unlabeled oligonucleotide probes and a saturating DNA dye[J]. Clin Chem,2004,50(8):1328-1335.
17	LEE V H, TIN V P, CHOY T S,et al.Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer[J]. J Thorac Oncol,2013,8(9):1148-1155.
18	李俭杰,曲莉莉,卫星,等. EGFR-TKI一线治疗EGFR基因突变的晚期非小细胞肺癌临床观察[J]. 中国肺癌杂志,2012,15(5):299-304.
19	XU X W,WENG X H,WANG C L,et al.Detection EGFR exon 19 status of lung cancer patients by DNA electrochemical biosensor[J]. Biosens Bioelectron,2016,80: 411-417.
20	ZHENG D,YE X,ZHANG M Z,et al.Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance[J]. Sci Rep,2016,6:20913.
21	梁淑芳,郭晔,马克威. 不同EGFR突变状态晚期肺腺癌患者TKI治疗效果比较[J]. 吉林大学学报(医学版),2014,40(2):404-408.
22	王瑞娟,张建中,王萍. ER与EGFR在非小细胞肺癌组织中的表达及其意义[J]. 肿瘤学杂志,2010,16(8):620-623.
23	林良安,刘志艺,杨建胜,等. EGFR突变在Ⅰ期非小细胞肺癌患者中的分布趋势[J]. 中华胸心血管外科杂志,2014,30(9):547-549.
24	PAEZ J G,JNNE P A,LEE J C,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science,2004,304(5676):1497-1500.
25	SIEGFRIED J M.Women and lung cancer: does oestrogen play a role?[J]. Lancet Oncol,2001, 2(8): 506-513.
26	STABILE L P,LYKER J S,GUBISH C T,et al.Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects[J]. Cancer Res,2005,65(4):1459-1470.
27	龚竹,邹国荣,曹小龙,等. 肺腺癌EGFR突变患者一线化疗与靶向治疗生存分析[J]. 海南医学,2016,27(3):367-370.
28	MU X L, LI L Y,ZHANG X T,et al.Gefitinib- sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer[J]. Clin Cancer Res,2005,11(12):4289-4294.
29	魏冰,王慧娟,马杰,等. 肺腺癌组织中EGFR-19和21外显子突变状况分析[J]. 河南医学研究,2010,19(4):407-410.
30	李迎雪,温文娟,韩琳,等. 应用ARMS检测不同类型的肺腺癌标本EGFR基因突变[J]. 临床与实验病理学杂志,2015,31(6):700-702.

项目	例数	EGFR		阳性率（%）	χ²值	P值
项目	例数	阳性例数	阴性例数	阳性率（%）	χ²值	P值
性别					8.893	0.003
男	105	39	66	37.1
女	102	59	43	57.8
年龄					2.576	0.631
<45岁	17	7	10	41.2
45~59岁	61	27	34	44.3
60~74岁	104	54	50	51.9
75~90岁	24	10	14	41.7
>90岁	1	0	1	0
病理分类					18.752	0.000
腺癌	181	96	85	53.0
鳞癌	13	1	12	7.7
其他	13	1	12	7.7

项目	例数	EGFR		阳性率（%）	χ²值	P值
项目	例数	阳性例数	阴性例数	阳性率（%）	χ²值	P值
性别					8.893	0.003
男	105	39	66	37.1
女	102	59	43	57.8
年龄					2.576	0.631
<45岁	17	7	10	41.2
45~59岁	61	27	34	44.3
60~74岁	104	54	50	51.9
75~90岁	24	10	14	41.7
>90岁	1	0	1	0
病理分类					18.752	0.000
腺癌	181	96	85	53.0
鳞癌	13	1	12	7.7
其他	13	1	12	7.7

项目	例数	EGFR			χ²值	P值
项目	例数	19del	L858R	其他	χ²值	P值
性别					0.487	0.784
男	39	18	19	2
女	59	28	26	5
年龄					7.926	0.244
<45岁	7	4	1	2
45~59岁	27	13	13	1
60~74岁	54	25	25	4
75~90岁	10	4	6	0
>90岁	0	0	0	0
病理分类
腺癌	96	45	44	7
鳞癌	1	0	1	0
其他	1	1	0	0

项目	例数	EGFR			χ²值	P值
项目	例数	19del	L858R	其他	χ²值	P值
性别					0.487	0.784
男	39	18	19	2
女	59	28	26	5
年龄					7.926	0.244
<45岁	7	4	1	2
45~59岁	27	13	13	1
60~74岁	54	25	25	4
75~90岁	10	4	6	0
>90岁	0	0	0	0
病理分类
腺癌	96	45	44	7
鳞癌	1	0	1	0
其他	1	1	0	0

肺腺癌分类	例数	EGFR
肺腺癌分类	例数	阴性	19del	L858R	其他
浸润前病变	13	9	3	1	0
微浸润性腺癌	41	24	6	8	3
浸润性腺癌	75	25	23	24	3
浸润性腺癌变异	3	3	0	0	0
合计	132	61	32	33	6